We treated established EO771-GFP and EO771-Bic tumors with anti–PD-L1 mAbs and observed that EO771-Bic tumors were more sensitive throughout the treatment cycle, as determined by percentage of tumor inhibition (Figure 7, E and F). The gene discussed is MIR155HG; the disease is neoplasm.